Menu Button
About Us
Approach
PNT001 program
Clinical strategy
Tauopathies
News
Press Releases/News
All
2021
2020
2019
June 17, 2021
Pinteon Therapeutics Announces $3 Million Award from Advanced Technology International to Support Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury
April 6, 2021
Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury
February 1, 2021
Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001
January 28, 2021
Pinteon Therapeutics Announces Upcoming Scientific Presentations
May 6, 2020
Pinteon Therapeutics Announces Scientific Advisory Board for Traumatic Brain Injury
October 31, 2019
Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
June 17, 2021
Pinteon Therapeutics Announces $3 Million Award from Advanced Technology International to Support Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury
April 6, 2021
Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury
February 1, 2021
Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001
January 28, 2021
Pinteon Therapeutics Announces Upcoming Scientific Presentations
May 6, 2020
Pinteon Therapeutics Announces Scientific Advisory Board for Traumatic Brain Injury
October 31, 2019
Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
About Us
Approach
PNT001 program
Clinical strategy
Tauopathies
News
